Showing results (261-270 of 395) with videos related to
Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2001
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancerM Colleoni, S Gelber, A S Coates, et al.The Lancet. Oncology|February 19, 2013
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)Bernhard C Pestalozzi, Eileen Holmes, Evandro de Azambuja, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid TumorsMartine J Piccart, Florentine S Hilbers, Judith M Bliss, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatmentVirginia Kimball Dalton, Montse Rue, Lewis B Silverman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFTOlivia Pagani, Prudence A Francis, Gini F Fleming, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicityDeborah P Waber, Lewis B Silverman, Lori Catania, et al.Breast Cancer Research and Treatment|July 4, 2016
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00Giancarlo Pruneri, Kathryn P Gray, Andrea Vingiani, et al.Breast Cancer Research and Treatment|March 29, 2018
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00Elisabetta Munzone, Kathryn P Gray, Caterina Fumagalli, et al.Seminars in Oncology|March 26, 2023
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysisLaura Pala, Tommaso De Pas, Eleonora Pagan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT TrialsMeredith M Regan, Prudence A Francis, Olivia Pagani, et al.Pageof 40